PPMI

1 3 2 **AV-133 ELIGIBILITY** 1 1

SUBJECT ID | | | | | VISIT NO | | | |

INITIALS | | | | SITE NO | | | | VISIT DATE | | | MM | | DD | | | | | YYYY

A. ☐ Check box if subject signed consent to participate in the ^{18}F-AV-133-PPMI companion protocol.

B. Date informed consent for participation in ^{18}F-AV-133-PPMI companion protocol was signed: B. | | MM | | DD | | | | | YYYY

SUBJECT INCLUSION CRITERIA (0 = No, 1 = Yes)

1. Women of childbearing potential must be using effective method of birth control 14 days prior to until at least 24 hours after injection of ^{18}F-AV-133. 1. ☐

To be **ELIGIBLE** for study participation item 1 must be 1 = YES if female of childbearing potential

SUBJECT EXCLUSION CRITERIA (0 = No, 1 = Yes)

1. Current clinically significant cardiovascular disease or clinically important abnormalities on screening ECG (including but not limited to QTc > 450 msec), prior to the first ^{18}F-AV-133 injection. 1. ☐

2. Currently taking medications that are known to cause QT-prolongation. 2. ☐

3. Currently taking tetrabenazine (TBZ) or amphetamine type medications. 3. ☐

4. Received any of the following medications that might interfere with PET imaging: neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine or amphetamine derivative, within 2 weeks of the screening ^{18}F-AV-133 injection. 4. ☐

5. Current clinically significant endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer (excluding localized basal cell carcinoma and in situ prostate cancer) that would interfere with completion of the study. 5. ☐

6. Have had prior intracranial surgery that would be expected to alter imaging. 6. ☐

To be **ELIGIBLE** for study participation **ALL** answers to items 1-6 must be **0 = No**